Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or higher for ten consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2). This development ensures LXRX's continued listing on the Nasdaq exchange.

Positive

• Regained Nasdaq listing compliance, avoiding potential delisting
• Maintained stock price above $1.00 for required period

Negative

• Previous trading below $1.00 threshold indicates recent financial challenges

News Market Reaction – LXRX

+4.90%

8 alerts

+4.90% Session move

+2.8% Peak in 3 hr 43 min

$401.31M Market Cap

0.4x Rel. Volume

In the trading session that priced this news, LXRX gained 4.90%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq’s listing qualifications staff has determined that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

This update was previously disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2025.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com. 

For Investor and Media Inquiries: 
Lisa DeFrancesco  
Lexicon Pharmaceuticals, Inc. 
lexinvest@lexpharma.com 

FAQ

What Nasdaq compliance requirement did Lexicon Pharmaceuticals (LXRX) meet in July 2025?

Lexicon Pharmaceuticals met Nasdaq's minimum bid price requirement by maintaining a closing bid price of $1.00 or higher for ten consecutive business days, complying with Nasdaq Listing Rule 5550(a)(2).

When did LXRX regain Nasdaq compliance?

Lexicon Pharmaceuticals regained Nasdaq compliance as confirmed on July 31, 2025, following ten consecutive business days of meeting the minimum bid price requirement.

What is the minimum bid price requirement for Nasdaq listing?

The Nasdaq minimum bid price requirement (Rule 5550(a)(2)) requires companies to maintain a closing bid price of $1.00 or higher for their common stock.

What happens if a company fails to meet Nasdaq's minimum bid price requirement?

Companies failing to meet the minimum bid price requirement risk delisting from Nasdaq if they cannot maintain a closing bid price of $1.00 or higher for at least ten consecutive business days during their compliance period.